Infections during a 7-Year Retrospective Analysis (2016-2022): Epidemiological, Clinical Features and Outcomes in Patients with Legionnaires' Disease.

Tommaso Lupia, Silvia Corcione, Nour Shbaklo, Barbara Rizzello, Ilaria De Benedetto, Erika Concialdi, Anna Sara Navazio, Maurizio Penna, Maria Teresa Brusa, Francesco Giuseppe De Rosa
Author Information
  1. Tommaso Lupia: Unit of Infectious Diseases, Cardinal Massaia, 14100 Asti, Italy. ORCID
  2. Silvia Corcione: Department of Medical Sciences, Infectious Diseases, University of Turin, 10126 Turin, Italy.
  3. Nour Shbaklo: Department of Medical Sciences, Infectious Diseases, University of Turin, 10126 Turin, Italy. ORCID
  4. Barbara Rizzello: Department of Medical Sciences, Infectious Diseases, University of Turin, 10126 Turin, Italy.
  5. Ilaria De Benedetto: Department of Medical Sciences, Infectious Diseases, University of Turin, 10126 Turin, Italy.
  6. Erika Concialdi: Microbiology Unit, Cardinal Massaia Hospital, 14100 Asti, Italy.
  7. Anna Sara Navazio: Microbiology Unit, Cardinal Massaia Hospital, 14100 Asti, Italy.
  8. Maurizio Penna: Microbiology Unit, Cardinal Massaia Hospital, 14100 Asti, Italy.
  9. Maria Teresa Brusa: Unit of Infectious Diseases, Cardinal Massaia, 14100 Asti, Italy.
  10. Francesco Giuseppe De Rosa: Unit of Infectious Diseases, Cardinal Massaia, 14100 Asti, Italy. ORCID

Abstract

(LP) is one of the main causative agents of community-acquired pneumonia in Europe and its fifth bacterial cause in Italy (4.9%). We conducted a seven year retrospective analysis of LP infection serogroup 1 in Asti, Piedmont, between 2016 and 2022. Patients were included if they tested positive for the urinary antigen. Clinical, laboratory, and radiologic data were analyzed to describe the risk factors for mortality. Fifty patients with LD were collected, mainly male, with a median age of 69 years. The main comorbidities were cardiovascular diseases (50%), pulmonary diseases (26%), and neurological diseases (12%). The most common clinical presentations were fever, respiratory, gastrointestinal, and neurologic symptoms. Older age ( = 0.004), underlying cardiovascular diseases ( = 0.009), late diagnosis at admission ( = 0.035), and neurological symptoms at diagnosis ( = 0.046) were more common in the non-survivor group. Moreover, a septic-shock presentation or the need for non-invasive ventilation at admission were associated with a higher mortality. No considerable differences in the biochemical data were found between the two groups except for the median neutrophil count, lymphocyte count, neutrophil-to-lymphocyte ratio, and PCT value. We did not find any differences in mortality related to the choice of antibiotic regimen. Differences in outcome were associated with the median duration of treatment ( =< 0.001) but not to the choice of antibiotic regimen (mainly levofloxacin or azithromycin). In conclusion, early individuation of the wide spectrum of clinical characteristics of LP infection such as respiratory, cardiac, and neurological manifestations of the patient's comorbidities, and significant biochemical data should help clinicians flag high risk patients and potentially improve their outcome.

Keywords

References

  1. Lancet Infect Dis. 2014 Oct;14(10):1011-21 [PMID: 24970283]
  2. JAMA. 2016 Feb 23;315(8):801-10 [PMID: 26903338]
  3. Exp Gerontol. 2019 Sep;124:110632 [PMID: 31201918]
  4. Eur J Clin Microbiol Infect Dis. 1996 Apr;15(4):286-90 [PMID: 8781878]
  5. JAMA. 1996 Jan 10;275(2):134-41 [PMID: 8531309]
  6. BMC Anesthesiol. 2014 May 21;14:37 [PMID: 24932132]
  7. Clin Infect Dis. 1998 Dec;27(6):1479-86 [PMID: 9868664]
  8. Clin Microbiol Rev. 1988 Jan;1(1):60-81 [PMID: 3060246]
  9. N Engl J Med. 2016 Feb 4;374(5):497-8 [PMID: 26840151]
  10. Eur J Clin Microbiol Infect Dis. 2009 Jan;28(1):55-60 [PMID: 18677519]
  11. Arch Bronconeumol. 2014 Jun;50(6):250-4 [PMID: 24387877]
  12. Semin Respir Crit Care Med. 2009 Apr;30(2):127-35 [PMID: 19296412]
  13. Microorganisms. 2022 Nov 24;10(12): [PMID: 36557579]
  14. J Infect. 1996 Nov;33(3):185-91 [PMID: 8945708]
  15. Eur Respir J. 2012 Apr;39(4):963-70 [PMID: 22005914]
  16. Lancet. 2016 Jan 23;387(10016):376-385 [PMID: 26231463]
  17. Arch Intern Med. 1996 Aug 12-26;156(15):1685-92 [PMID: 8694667]
  18. Infection. 2021 Apr;49(2):321-325 [PMID: 33315182]
  19. Health Sci Rep. 2022 May 02;5(3):e630 [PMID: 35509390]
  20. AJR Am J Roentgenol. 1983 Aug;141(2):263-8 [PMID: 6603115]
  21. Respir Med Case Rep. 2019 Oct 28;28:100962 [PMID: 31720209]
  22. Pneumonol Alergol Pol. 2013;81(4):399-403 [PMID: 23744171]
  23. N Engl J Med. 1977 Dec 1;297(22):1189-97 [PMID: 335244]
  24. Infect Dis Clin North Am. 2017 Mar;31(1):55-68 [PMID: 27979685]
  25. Microorganisms. 2021 Oct 20;9(11): [PMID: 34835307]
  26. Infect Immun. 2004 Jul;72(7):4040-51 [PMID: 15213149]
  27. J Infect. 2002 Oct;45(3):199-201 [PMID: 12387779]
  28. Int J Infect Dis. 2021 Feb;103:42-47 [PMID: 33176204]
  29. Clin Lab Med. 2014 Jun;34(2):219-36 [PMID: 24856525]
  30. N Engl J Med. 1977 Dec 1;297(22):1197-203 [PMID: 335245]
  31. Curr Microbiol. 2005 Jan;50(1):43-6 [PMID: 15723146]
  32. Clin Infect Dis. 2021 Jun 1;72(11):1979-1989 [PMID: 32296816]
  33. Am J Respir Crit Care Med. 1997 Nov;156(5):1467-72 [PMID: 9372662]
  34. J Clin Med. 2021 May 01;10(9): [PMID: 34062864]
  35. Clin Microbiol Rev. 2002 Jul;15(3):506-26 [PMID: 12097254]
  36. Ann Intern Med. 1979 Apr;90(4):526-8 [PMID: 434629]
  37. Medicine (Baltimore). 1984 Sep;63(5):303-10 [PMID: 6088942]
  38. Infect Drug Resist. 2022 Apr 27;15:2219-2228 [PMID: 35510157]
  39. J Immunol. 2001 Mar 1;166(5):3355-61 [PMID: 11207291]
  40. Infect Immun. 1995 Sep;63(9):3609-20 [PMID: 7642298]

Word Cloud

Created with Highcharts 10.0.00diseases=LPdatamortalitymedianneurologicalmainpneumoniainfectionPatientsurinaryantigenClinicalriskpatientsmainlyagecomorbiditiescardiovascularcommonclinicalrespiratorysymptomsdiagnosisadmissionassociateddifferencesbiochemicalcountneutrophil-to-lymphocyteratiochoiceantibioticregimenoutcomeonecausativeagentscommunity-acquiredEuropefifthbacterialcauseItaly49%conductedsevenyearretrospectiveanalysisserogroup1AstiPiedmont20162022includedtestedpositivelaboratoryradiologicanalyzeddescribefactorsFiftyLDcollectedmale69years50%pulmonary26%12%presentationsfevergastrointestinalneurologicOlder004underlying009late035046non-survivorgroupMoreoverseptic-shockpresentationneednon-invasiveventilationhigherconsiderablefoundtwogroupsexceptneutrophillymphocytePCTvaluefindrelatedDifferencesdurationtreatment=<001levofloxacinazithromycinconclusionearlyindividuationwidespectrumcharacteristicscardiacmanifestationspatient'ssignificanthelpcliniciansflaghighpotentiallyimproveInfections7-YearRetrospectiveAnalysis2016-2022:EpidemiologicalFeaturesOutcomesLegionnaires'DiseaseLegionellaLegionnairesdiseaselymphopenia

Similar Articles

Cited By